In:
Current Cancer Therapy Reviews, Bentham Science Publishers Ltd., Vol. 16 ( 2020-10-16)
Abstract:
Prostate Cancer (PC) is one the most prominent cause of deaths in males worldwide especially in western
countries. The exhaustive research into prostate cancer to date has demonstrated ELAC2, RNASEL, MSR1, NBS1, CHEK2, MYC, BCL-2, c-Kit, tumor suppressor genes, BRCA1, BRCA2, PACE4, GSTP1, PTEN,CDKN1B, NKX3.1,
KLF6, FOXA1, Retinoblastoma, p53, androgen receptor, kallikreins, ETS, CYP17, SRD5A2, E-cadherin, KAI1/CD82, hepsin, AMACR, PIM1, MTA-1, EZH2, EPHB2, growth factors & its receptors, cannabinoid receptors, annexins,
oxidative stress and inflammation are entailed changes underlying the initiation, development, and progression of PC. Furthermore, oncology would shift from a reactive to proactive discipline so exploring these targets open new area of
research. Therefore, the present review is focused on molecular pathophysiology biomarkers for the progression of PC that would encourage the researchers and pharmaceutical industries to investigate potential therapeutic strategy to
overcome demerits of currently available clinically therapies.
Type of Medium:
Online Resource
ISSN:
1573-3947
DOI:
10.2174/1573394716999201016155640
Language:
English
Publisher:
Bentham Science Publishers Ltd.
Publication Date:
2020
Bookmarklink
